Digestive cancers are among the most common and deadly cancers in the world, comprising metastases of the colon, esophagus, stomach and rectum.   These all share some cellular commonalities, namely the presentation of a molecular signature that can now be a target for engineered therapies.  Dr. Adam Snook has been studying the fingerprints of gastric cancers and developing gene therapy approaches that target cancer cells.  He discusses the technology, and describes how it works, and how the technology has changed in response to new findings. Dr. Snook provides a forward-thinking and hopeful view of how this technology may soon provide a needed therapy against common cancers.

Follow Dr. Snook on Twitter:  @adamsnookphd

Dr. Snook’s website is here.